Skip over navigation
The Hospital
Research
Support Us
Ottawa Hospital Research Institute
Home
Français
Directions & Maps
Contact Us
About Us
Vision and Strategic Directions
Board Chair and CEO Message
Leadership Team
Annual Reports
Facilities
Research Data Management
Equity, Diversity and Inclusion
Wellness
Our Research
Priorities, Programs and Diseases
Researcher Profiles
National Research Networks
Scientific Publications
Research Awards
Technology Transfer
Industry Sponsored Research
Responsible Innovation
For Students & Fellows
News & Events
Newsroom
Seminars & Events
Career Opportunities
For Patients
News & Events
Home
>
News & Events
>
Newsroom
Bookmark or Share
Display Options
Display Options
+
Increase
/
-
Decrease
font size
High contrast version
Printer-friendly version
Newsroom
Seminars & Events
Newsroom
Study raises questions about effectiveness of biomarkers used in cancer treatments
June 24, 2014
Dr.
Mark Clemons
has published a study in
Breast Cancer Research and Treatment
that is the first to demonstrate how changing an anti-cancer therapy can result in significant changes to bone turnover biomarkers. This is important because these biomarkers are commonly used in clinical trials to measure the effectiveness of bone-targeted medicines and treatments. Dr. Clemons stumbled upon this discovery while exploring whether the anti-cancer drug Vandetanib would work well in combination with Fulvestrant when given to postmenopausal breast cancer patients whose cancer has spread to the bone. While the pan-Canadian study found that Vandetinib did not improve the effectiveness of Fulvestrant, it did show that changing an anti-cancer therapy can result in significant changes in bone turnover biomarkers. Previously, it was thought that these biomarkers only changed in response to bone-targeted agents like bisphosphonates. Dr. Clemons` finding calls into question the widespread use of these biomarkers in breast cancer trials.
Read the study
.
About the Ottawa Hospital Research Institute
The Ottawa Hospital Research Institute (OHRI) is the research arm of The Ottawa Hospital and is an affiliated institute of the University of Ottawa, closely associated with the university’s Faculties of Medicine and Health Sciences. OHRI includes more than 1,700 scientists, clinical investigators, graduate students, postdoctoral fellows and staff conducting research to improve the understanding, prevention, diagnosis and treatment of human disease.
Media contact
Paddy Moore
Communications and Public Relations
Ottawa Hospital Research Institute
613-737-8899 x73687
613-323-5680 (cell)